NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $3.51 +0.12 (+3.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.56 +0.05 (+1.28%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Genelux Stock (NASDAQ:GNLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genelux alerts:Sign Up Key Stats Today's Range$3.32▼$3.5650-Day Range$2.45▼$3.6052-Week Range$1.60▼$5.89Volume66,738 shsAverage Volume155,977 shsMarket Capitalization$132.54 millionP/E RatioN/ADividend YieldN/APrice Target$17.75Consensus RatingBuy Company Overview Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California. Read More Genelux Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreGNLX MarketRank™: Genelux scored higher than 35% of companies evaluated by MarketBeat, and ranked 727th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 2 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.88) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.07% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Genelux has recently decreased by 0.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.07% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Genelux has recently decreased by 0.43%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.77 News SentimentGenelux has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genelux this week, compared to 1 article on an average week.Search Interest6 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows4 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.30% of the stock of Genelux is held by insiders.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address GNLX Stock News HeadlinesGenelux Corporation (NASDAQ:GNLX) Receives $17.75 Average PT from BrokeragesJuly 30 at 2:51 AM | americanbankingnews.comLUCID CAPITAL MARKETS Initiates Coverage of Genelux (GNLX) with Buy RecommendationJuly 22, 2025 | msn.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.August 2 at 2:00 AM | InvestorPlace (Ad)Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business DevelopmentJuly 7, 2025 | quiverquant.comQGenelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business DevelopmentJuly 7, 2025 | globenewswire.comGenelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business UpdatesMay 6, 2025 | globenewswire.comBenchmark Co. Remains a Buy on Genelux Corp. (GNLX)April 9, 2025 | markets.businessinsider.comGuggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)April 5, 2025 | markets.businessinsider.comSee More Headlines GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $2.36 at the beginning of the year. Since then, GNLX stock has increased by 48.7% and is now trading at $3.51. How were Genelux's earnings last quarter? Genelux Corporation (NASDAQ:GNLX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Top institutional shareholders of Genelux include Woodward Diversified Capital LLC (4.71%), LifeSteps Financial Inc. (0.26%), Falcon Wealth Planning (0.06%) and Beacon Capital Management LLC (0.05%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genelux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNLX CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Genelux$17.75 High Price Target$30.00 Low Price Target$8.00 Potential Upside/Downside+405.7%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.87 million Net MarginsN/A Pretax Margin-373,362.47% Return on Equity-93.04% Return on Assets-74.17% Debt Debt-to-Equity RatioN/A Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book4.62Miscellaneous Outstanding Shares37,761,000Free Float34,249,000Market Cap$132.54 million OptionableNot Optionable Beta-0.34 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:GNLX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.